Video

Dr. Gupta discusses bladder cancer research highlights from ASCO 2021

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, gives an overview of key bladder cancer research from the 2021 American Society of Clinical Oncology annual meeting. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
October 11th 2024

Upper tract urothelial carcinoma: An in-depth review for urologists

Jesse Persily, MD Sameer Thakker, MD Katie S. Murray, DO, MS
"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC
October 9th 2024

Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC

Hannah Clarke
"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive disease," says Andrea Necchi, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Device-related problems and event rates for PEG hydrogel spacers appear low
October 3rd 2024

Device-related problems and event rates for PEG hydrogel spacers appear low

Hannah Clarke
The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
October 3rd 2024

Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC

Hannah Clarke
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
© 2024 MJH Life Sciences

All rights reserved.